R135
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 28
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.540
- E2F_TARGETS+0.510
- INTERFERON_ALPHA_RESPONSE+0.510
- MYC_TARGETS_V1+0.460
- PROTEIN_SECRETION+0.450
- MTORC1_SIGNALING+0.340
- ANDROGEN_RESPONSE+0.310
- OXIDATIVE_PHOSPHORYLATION+0.290
- SPERMATOGENESIS+0.280
- INTERFERON_GAMMA_RESPONSE+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- ANGIOGENESIS-0.480
- HEDGEHOG_SIGNALING-0.410
- MYOGENESIS-0.410
- APICAL_JUNCTION-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- COAGULATION-0.370
- NOTCH_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- APICAL_SURFACE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797282 | — | cohortSC | 0.893 |
| 2 | R137 | — | — | 0.892 |
| 3 | SRR11296733 | — | — | 0.885 |
| 4 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.875 |
| 5 | 48507_S107 | — | cohortMD1 | 0.862 |
| 6 | SRR11296797 | — | — | 0.859 |
| 7 | TCGA-AC-A2BM-01A-11R-A21T-07 | — | B | 0.854 |
| 8 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.854 |
| 9 | 131544 | EPN | EPN Tumor | 0.853 |
| 10 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |